berobenatide

News

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.